Metastatic Bladder Giant Cell Urothelial Carcinoma

Explore clinical trials studying Metastatic Bladder Giant Cell Urothelial Carcinoma. Study availability and eligibility vary by location and protocol.

2 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Metastatic Bladder Giant Cell Urothelial Carcinoma trial results

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT03866382

Conditions: Adenocarcinoma, Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, +71 more
Locations: University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States

Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States

Anchorage Radiation Therapy Center Anchorage, Alaska, United States

Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States

View all 582 locations

View Trial Details

Not Yet Recruiting

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

NCT07667335

Conditions: Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Locally Advanced Bladder Urothelial Carcinoma, +23 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Metastatic Bladder Giant Cell Urothelial Carcinoma

Metastatic Bladder Giant Cell Urothelial Carcinoma trial results

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

Related conditions